A newly anti-VEGF drug brolucizumab is the smallest molecule weight of a 28 kDa humanized single-chain antibody fragment and has been approved to use unprecedented 12-week dosing schedule, which can be able to achieve dry macular and prevent frequent visits for AMD patients [10,11]. This evidence concerns the gene VEGFA and age-related macular degeneration.